Norman Callahan, DO
Gastroenterology · Malvern, PANPI 1851367783
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 479 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 30.8% of the total. 2025 is the largest year on record at $1,863, 2.1 times the $903 reported in 2019.
Across 479 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$1K
- Bristol Myers Squibb$853
- Pfizer$689
- Takeda Pharmaceuticals U.S.A., Inc.$650
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$591
- plus $2K from 25 others
Across 1 payment — averaging $118.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$119
What the payments were for
- Food & beverage$8,77199%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 152 | $2,721 |
| Johnson & Johnson | 48 | $1,105 |
| Bristol Myers Squibb | 53 | $853 |
| Pfizer | 48 | $689 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $650 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 41 | $591 |
| Ardelyx, Inc. | 16 | $321 |
| Sanofi | 9 | $206 |
| QOL Medical, LLC | 8 | $197 |
| Madrigal Pharmaceuticals | 6 | $171 |
| Intercept Pharmaceuticals, Inc. | 10 | $162 |
| Ferring Pharmaceuticals Inc. | 3 | $141 |
| Regeneron Healthcare Solutions, Inc. | 6 | $138 |
| Amgen | 5 | $129 |
| Gilead | 8 | $121 |
| Phathom Pharmaceuticals, Inc. | 6 | $95 |
| Celltrion USA Inc. | 3 | $83 |
| Merck | 4 | $80 |
| Lilly USA, LLC | 3 | $57 |
| Aimmune Therapeutics, Inc. | 2 | $51 |
| Inspire Medical Systems, Inc. | 2 | $37 |
| Alfasigma USA, Inc. | 2 | $37 |
| Endo Pharmaceuticals Inc. | 2 | $35 |
| Boston Scientific | 2 | $30 |
| Braintree Laboratories, Inc. | 2 | $25 |
| Shield Therapeutics Inc | 1 | $25 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Vivus LLC | 1 | $18 |
| Axonics, Inc. | 1 | $16 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,837 in reported general payments places this provider in the 80th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 36 | $986,952 |
| CreonLipase/Protease/Amylase | 11 | $45,175 |
| LinzessLinaclotide | 15 | $17,479 |
| Dexlansoprazole DrDexlansoprazole | 21 | $9,426 |
| Pantoprazole Sodium | 223 | $3,351 |
| Budesonide DrBudesonide | 19 | $2,892 |
| Omeprazole | 267 | $2,882 |
| Ursodiol | 15 | $2,549 |
| Colestipol Hcl | 12 | $1,302 |
| CholestyramineCholestyramine (With Sugar) | 20 | $606 |
| Famotidine | 58 | $539 |
| Dicyclomine Hcl | 17 | $421 |
| Esomeprazole Magnesium | 14 | $233 |
| Amitriptyline Hcl | 16 | $131 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,105 | $986,95236 claims |
| AbbVieCreon, Linzess | $2,721 | $62,65426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 gastroenterology providers in Pennsylvania.
Other gastroenterology in Malvern
- Rupal KothariMalvern$61K
- Miguel RegueiroPittsburgh$1.5M
- Adam PeytonAllentown$985K
- Shahin RahimianWaynesboro$592K
- Sandra El-HachemPittsburgh$472K
- Harshit KharaDanville$438K
- Kofi ClarkeHershey$426K
- Michael KochmanPhiladelphia$361K
- Gary LichtensteinPhiladelphia$342K
- Elie AounPittsburgh$323K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.